Physician profile
Elvis Rosero
NPI 1942461157
$502.58
in general payments reported to CMS, 2019-2025
10 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.56 · 2022: $28.80 · 2023: $161 · 2024: $184 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $152.07 | 2022-2025 | Nuzyra |
| Stryker Corporation | $98.01 | 2024 | Variax |
| Treace Medical Concepts, INC. | $93.74 | 2022-2025 | |
| Medtronic, INC. | $50.80 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Integra Lifesciences Corporation | $20.85 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Melinta Therapeutics, LLC | $19.56 | 2019 | |
| Reprise Biomedical, INC. | $17.36 | 2023 | Miro3d |
| Convatec INC. | $17.25 | 2023 | |
| Nevro Corp. | $16.51 | 2023 | Senza |
| Sebela Pharmaceuticals INC. | $16.43 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elvis Rosero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.